Anders Abildgaard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anders Abildgaard has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Gregers Wegener
Aarhus University
8 shared publications - Sten Lund
Department of Internal Medicine and Endocrinology, Aarhus University Hospital, Aarhus, Denmark
7 shared publications - Betina Elfving
Translational Neuropsychiatry Unit A601, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
3 shared publications Julie Støy
Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark
3 shared publications- Kristina Laugesen
Department of Clinical Biochemistry, Aarhus University Hospital , Aarhus
3 shared publications Marianne Hokland
C Department of Biomedicine , Aarhus University , Aarhus , Denmark
3 shared publications
Latest Publications
- 4 November 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (11)
Comment on: Pregnancy complications and birth outcomes in women with antiphospholipid antibodies: a Danish population-based cohort study: reply
- 4 November 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (11)
Comment on: Pregnancy complications and birth outcomes in women with antiphospholipid antibodies: a Danish population-based cohort study: reply
- Open Access
- 3 November 2026
- Published by Wiley in International Journal of Laboratory Hematology
Optimization of Leukocytic Flags in the Sysmex‐ XN Series With the Help of Flow Cytometric Differential ( FlowDiff ) Can Significantly Optimize Laboratory Efficiency
Objectives: The aim of this study was to adjust the default white blood cell (WBC) differential count flag settings on the Sysmex XN‐9100 haematology analyser to reduce unnecessary additional leukocyte differential counts without compromising diagnostic sensitivity. Methods: Data from 4554 routine blood samples flagged on Sysmex XN‐9100 and corresponding additional leukocyte differential counts performed on the Sysmex XF‐1600 flow cytometer were used to optimise the WBC flagging rules. Results: A total of 1148 samples had scattergram‐related flags, which are non‐adjustable. Optimal cut points for Q‐flags were established based on Youden's Index for the remaining 3406 samples, while the diagnostic sensitivity of the new flagging rules for acute leukaemia was assessed in a validation cohort. The optimal cut points for Q‐flags were 120 for ‘Atypical Lymphocytes’, 170 for ‘Abnormal Lymphocytes’ and 160 for ‘Blasts’, while the Q‐flag ‘Left shift’ offered no diagnostic value in our cohort. The count flags ‘eosinophilia’, ‘basophilia’ and ‘monocytopenia’ were deactivated, as the results from Sysmex XN were comparable to the flow cytometric reference method. By implementing the new flagging rules, 1709 (37.5%) of the samples would have been processed without need for additional leukocyte differential count. When evaluated in a separate validation cohort of 90 samples from patients with newly diagnosed acute leukaemia, the new rules showed similar diagnostic sensitivity to the default flagging system. Conclusion: Optimisation of Sysmex flagging rules for leukocyte differential counts was feasible and significantly reduced unnecessary reflex testing, while maintaining analytical accuracy and diagnostic safety.
- 3 November 2026
- Published by Wiley in International Journal of Laboratory Hematology
Open AccessOptimization of Leukocytic Flags in the Sysmex‐ XN Series With the Help of Flow Cytometric Differential ( FlowDiff ) Can Significantly Optimize Laboratory Efficiency
Objectives: The aim of this study was to adjust the default white blood cell (WBC) differential count flag settings on the Sysmex XN‐9100 haematology analyser to reduce unnecessary additional leukocyte differential counts without compromising diagnostic sensitivity. Methods: Data from 4554 routine blood samples flagged on Sysmex XN‐9100 and corresponding additional leukocyte differential counts performed on the Sysmex XF‐1600 flow cytometer were used to optimise the WBC flagging rules. Results: A total of 1148 samples had scattergram‐related flags, which are non‐adjustable. Optimal cut points for Q‐flags were established based on Youden's Index for the remaining 3406 samples, while the diagnostic sensitivity of the new flagging rules for acute leukaemia was assessed in a validation cohort. The optimal cut points for Q‐flags were 120 for ‘Atypical Lymphocytes’, 170 for ‘Abnormal Lymphocytes’ and 160 for ‘Blasts’, while the Q‐flag ‘Left shift’ offered no diagnostic value in our cohort. The count flags ‘eosinophilia’, ‘basophilia’ and ‘monocytopenia’ were deactivated, as the results from Sysmex XN were comparable to the flow cytometric reference method. By implementing the new flagging rules, 1709 (37.5%) of the samples would have been processed without need for additional leukocyte differential count. When evaluated in a separate validation cohort of 90 samples from patients with newly diagnosed acute leukaemia, the new rules showed similar diagnostic sensitivity to the default flagging system. Conclusion: Optimisation of Sysmex flagging rules for leukocyte differential counts was feasible and significantly reduced unnecessary reflex testing, while maintaining analytical accuracy and diagnostic safety.
- Open Access
- 7 August 2026
- Published by Elsevier in Endocrine Practice
Metformin and Vitamin B12 Deficiency: A Prevalence Study
- 7 August 2026
- Published by Elsevier in Endocrine Practice
Open AccessMetformin and Vitamin B12 Deficiency: A Prevalence Study
- 1 August 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (8)
Pregnancy complications and birth outcomes in women with antiphospholipid antibodies: a Danish population-based cohort study
Objectives: To provide the first population-based estimates of pregnancy complications, adverse birth outcomes and venous thromboembolism (VTE) among clinically selected women undergoing aPL testing, and to examine how risks vary by aPL status. Methods: We conducted a population-based cohort study in the Central Denmark Region (2012–2023), including pregnancies reaching GA10 in women with at least one aPL measurement before pregnancy. Pregnancies were classified by aPL status and APS-related outcomes were assessed according to the 2023 ACR/EULAR criteria. Generalized estimating equations were used to estimate risk ratios (RR), risk differences and mean differences with 95% confidence intervals (CI). Results: Among 2961 pregnancies, 137 (4.6%) were aPL-positive. Positive aPL was not associated with spontaneous abortion between GA10 + 0 and 15 + 6 or unexplained foetal death before GA34 + 0. However, aPL-positive pregnancies had higher risks of intrauterine growth restriction < GA34 (2.9% vs 1.0%; RR 3.00 [1.00–8.6]), VTE (1.5% vs 0.3%; RR 5.4 [1.14–26.0]) and late preterm birth (14% vs 6.4%; RR 2.28 [1.41–3.66]), and greater negative deviation from expected birth weight (adjusted mean difference −3.4% [−6.1−−0.73]). Substantially fewer APS-related events than expected resulted in imprecise estimates. aPL-negative women also had elevated risks compared with the general population. Conclusion: In this population-based cohort of clinically tested women, absolute risks associated with aPL positivity were lower than those reported in APS referral cohorts. These findings suggest that the prognostic implications of aPL positivity depend strongly on the clinical context of testing and should inform clinical risk assessment and counseling.
- 1 August 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (8)
Pregnancy complications and birth outcomes in women with antiphospholipid antibodies: a Danish population-based cohort study
Objectives: To provide the first population-based estimates of pregnancy complications, adverse birth outcomes and venous thromboembolism (VTE) among clinically selected women undergoing aPL testing, and to examine how risks vary by aPL status. Methods: We conducted a population-based cohort study in the Central Denmark Region (2012–2023), including pregnancies reaching GA10 in women with at least one aPL measurement before pregnancy. Pregnancies were classified by aPL status and APS-related outcomes were assessed according to the 2023 ACR/EULAR criteria. Generalized estimating equations were used to estimate risk ratios (RR), risk differences and mean differences with 95% confidence intervals (CI). Results: Among 2961 pregnancies, 137 (4.6%) were aPL-positive. Positive aPL was not associated with spontaneous abortion between GA10 + 0 and 15 + 6 or unexplained foetal death before GA34 + 0. However, aPL-positive pregnancies had higher risks of intrauterine growth restriction < GA34 (2.9% vs 1.0%; RR 3.00 [1.00–8.6]), VTE (1.5% vs 0.3%; RR 5.4 [1.14–26.0]) and late preterm birth (14% vs 6.4%; RR 2.28 [1.41–3.66]), and greater negative deviation from expected birth weight (adjusted mean difference −3.4% [−6.1−−0.73]). Substantially fewer APS-related events than expected resulted in imprecise estimates. aPL-negative women also had elevated risks compared with the general population. Conclusion: In this population-based cohort of clinically tested women, absolute risks associated with aPL positivity were lower than those reported in APS referral cohorts. These findings suggest that the prognostic implications of aPL positivity depend strongly on the clinical context of testing and should inform clinical risk assessment and counseling.
- 17 February 2025
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 85 (2) , 168-171
Short-term stability of routine coagulation tests under different storage temperatures in centrifuged whole blood samples: a practical approach
- 17 February 2025
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 85 (2) , 168-171
Short-term stability of routine coagulation tests under different storage temperatures in centrifuged whole blood samples: a practical approach
- Open Access
- 26 September 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 565, 119978
Exchangeable serum copper: Adult and pediatric reference intervals and in vitro stability in a nordic cohort
- 26 September 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 565, 119978
Open AccessExchangeable serum copper: Adult and pediatric reference intervals and in vitro stability in a nordic cohort
- Open Access
- 2 September 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (3) , 636-644
Clinical value of smear review of flagged samples analyzed with the Sysmex XN hematology analyzer
Objectives: A smear review is typically made in flagged differential counts performed with hematology analyzers although the clinical value of such reviews is uncertain. Therefore, we evaluated the differences in differential counts between Sysmex XN-9000 and a smear review in flagged samples. Furthermore, the clinical value of blasts identified was investigated. Methods: Data on all differential counts performed in a two-year period were identified at two laboratories. In patients with blasts, the electronic health record was reviewed. Agreement between automated and manual differential counts was evaluated by Bland-Altman plots. Concordance between the two methods categorized according to reference intervals was evaluated and adjusted for irrelevant non-concordance caused by random analytical error. Results: In total, 5,500 flagged differential counts were identified from 4,092 patients. A good agreement between the automated and manual differential count was found for all cell types (−0.480 × 10 9 /L to 0.297 × 10 9 /L). The concordance between the two methods was excellent for all cell types, except for monocytes (82 %) where the automated estimates were higher than the manual in 19 % of samples. Blasts were identified in 241 (1 %) of smear reviews. Acute leukemia was diagnosed in 13 (5 %) patients, and only in one patient contributed the detection of blasts to the suspicion of acute leukemia. Conclusions: Our findings indicate that routine smear review of all flagged samples do not contribute with additional, significant information. After local validation and dialogue with clinical departments, such reviews may potentially be omitted to increase cost-effectiveness and reduce turn-around-time.
- 2 September 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (3) , 636-644
Open AccessClinical value of smear review of flagged samples analyzed with the Sysmex XN hematology analyzer
Objectives: A smear review is typically made in flagged differential counts performed with hematology analyzers although the clinical value of such reviews is uncertain. Therefore, we evaluated the differences in differential counts between Sysmex XN-9000 and a smear review in flagged samples. Furthermore, the clinical value of blasts identified was investigated. Methods: Data on all differential counts performed in a two-year period were identified at two laboratories. In patients with blasts, the electronic health record was reviewed. Agreement between automated and manual differential counts was evaluated by Bland-Altman plots. Concordance between the two methods categorized according to reference intervals was evaluated and adjusted for irrelevant non-concordance caused by random analytical error. Results: In total, 5,500 flagged differential counts were identified from 4,092 patients. A good agreement between the automated and manual differential count was found for all cell types (−0.480 × 10 9 /L to 0.297 × 10 9 /L). The concordance between the two methods was excellent for all cell types, except for monocytes (82 %) where the automated estimates were higher than the manual in 19 % of samples. Blasts were identified in 241 (1 %) of smear reviews. Acute leukemia was diagnosed in 13 (5 %) patients, and only in one patient contributed the detection of blasts to the suspicion of acute leukemia. Conclusions: Our findings indicate that routine smear review of all flagged samples do not contribute with additional, significant information. After local validation and dialogue with clinical departments, such reviews may potentially be omitted to increase cost-effectiveness and reduce turn-around-time.
- 11 July 2024
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 84 (4) , 278-284
Diagnostic performance of the CellaVision preclassification neutrophil count – time to bypass the reclassification?
The objective of this study was to perform a method comparison between the CellaVision preclassification neutrophil count and the reclassification neutrophil count performed by trained laboratory technicians, and to evaluate the diagnostic performance of the preclassification neutrophil count at clinical decision levels. We retrospectively identified patient samples through 2019-2022 in which the differential count was performed on Cellavision (n = 4,354). Data on sample characteristics and leukocyte- and differential counts was extracted from the electronic medical journal. For each sample, data containing the pre- and reclassification leukocyte classification, respectively, was extracted from the Cellavision software. Method comparison between the pre-and reclassification neutrophil count was performed using Bland Altman analysis. Diagnostic performance of the preclassification neutrophil count was evaluated according to four pre-specified categories of results with the reclassification as reference method. The median difference between the pre- and reclassification neutrophil count was 0.044 x 109/L. The preclassification neutrophil count categorised 95.6% of all samples correctly according to the four categories. The sensitivity, specificity, positive predictive value and negative predictive value for detecting neutrophilia > 7.00 x 109/L was 98.8%, 97.2%, 95.8%, and 99.2%, respectively. In samples with leukopenia (n = 543), the sensitivity, specificity, positive predictive value and negative predictive value for detecting severe neutropenia (< 0.50 x 109/L) was 97.7%, 99.1%, 98.6%, and 98.5%, respectively. The diagnostic performance of the CellaVision preclassification neutrophil count was satisfactory. The preclassification neutrophil count may be released to the electronic medical journal to improve turnaround time and benefit laboratory management.
- 11 July 2024
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 84 (4) , 278-284
Diagnostic performance of the CellaVision preclassification neutrophil count – time to bypass the reclassification?
The objective of this study was to perform a method comparison between the CellaVision preclassification neutrophil count and the reclassification neutrophil count performed by trained laboratory technicians, and to evaluate the diagnostic performance of the preclassification neutrophil count at clinical decision levels. We retrospectively identified patient samples through 2019-2022 in which the differential count was performed on Cellavision (n = 4,354). Data on sample characteristics and leukocyte- and differential counts was extracted from the electronic medical journal. For each sample, data containing the pre- and reclassification leukocyte classification, respectively, was extracted from the Cellavision software. Method comparison between the pre-and reclassification neutrophil count was performed using Bland Altman analysis. Diagnostic performance of the preclassification neutrophil count was evaluated according to four pre-specified categories of results with the reclassification as reference method. The median difference between the pre- and reclassification neutrophil count was 0.044 x 109/L. The preclassification neutrophil count categorised 95.6% of all samples correctly according to the four categories. The sensitivity, specificity, positive predictive value and negative predictive value for detecting neutrophilia > 7.00 x 109/L was 98.8%, 97.2%, 95.8%, and 99.2%, respectively. In samples with leukopenia (n = 543), the sensitivity, specificity, positive predictive value and negative predictive value for detecting severe neutropenia (< 0.50 x 109/L) was 97.7%, 99.1%, 98.6%, and 98.5%, respectively. The diagnostic performance of the CellaVision preclassification neutrophil count was satisfactory. The preclassification neutrophil count may be released to the electronic medical journal to improve turnaround time and benefit laboratory management.
- 22 September 2023
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 42 (1) , 150-155
Deceived by Elevated A1C: Cases of Misdiagnosed Diabetes
- 22 September 2023
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 42 (1) , 150-155
Deceived by Elevated A1C: Cases of Misdiagnosed Diabetes